Anison Therapeutics Oy is a spin-off company from Åbo Akademi University, Turku, established in 2021, co-founded by the team of inventors behind the technology and the CEO. Anison Therapeutics aims at building a portfolio targeting the eradication of the Human Papillomavirus (HPV)-mediated diseases. The first steps are taken by dedicated efforts towards developing and commercializing a plant-based medication that addresses unmet medical needs for HPV-associated warts, especially genital warts.